Top-News

Virax Biolabs Group Aktie News

Aktie
WKN:  ISIN:  KYG9495L1251 US-Symbol:  VRAX
0,6128 $
-0,0312 $
-4,84%
0,5262 € 19:13:20 Uhr
Depot/Watchlist
Marktkapitalisierung *
656,20 Tsd. €
Streubesitz
-
KGV
-
Index-Zuordnung
-

Virax Biolabs Group News

04.12.25 - PR Newswire
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement PR Newswire
03.12.25 - PR Newswire
Virax Biolabs Group Limited Announces $5 Million Private Placement
Virax Biolabs Group Limited Announces $5 Million Private Placement PR Newswire
03.12.25 - PR Newswire
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders
Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders PR Newswire
03.11.25 - PR Newswire
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-Acute Infection Syndromes
Virax Biolabs Completes UK Clinical Recruitment and Reports Constructive FDA Feedback for ViraxImmune™ Study Evaluating T Cell Dysfunction in Post-​Acute Infection Syndromes ...
26.08.25 - PR Newswire
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September
Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-​Submission Meeting in Early September PR Newswire
29.07.25 - PR Newswire
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy PR Newswire
18.07.25 - PR Newswire
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency PR Newswire
18.03.25 - PR Newswire
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes
Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-​acute Infection Syndromes PR Newswire
13.03.25 - PR Newswire
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-​acute Infection Syndromes at the 19th World Immune Regulation Meeting PR Newswire
05.03.25 - PR Newswire
Virax Biolabs to Present at 19th World Immune Regulation Meeting
Virax Biolabs to Present at 19th World Immune Regulation Meeting PR Newswire
17.12.24 - PR Newswire
Virax Biolabs' CEO James Foster Issues Letter to Shareholders
Virax Biolabs' CEO James Foster Issues Letter to Shareholders PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »